Supernus Files for $100M IPO to Back CNS Delivery Pipeline
By Trista Morrison
Tuesday, December 28, 2010
The current initial public offering (IPO) window has not proven particularly welcoming for specialty pharmaceutical firms, but that didn't stop Supernus Pharmaceuticals Inc. from joining the queue with a $100 million filing.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.